SCHEMBL3969837

SCHEMBL3969837

COc1cc(CC#N)c(C(=O)N(C)C)cc1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 1/20 0.40
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
PDE3B Q13370 2/20 0.38
PDE3A Q14432 2/20 0.38
PDE5A O76074 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
ELANE P08246 1/20 0.37
NPSR1 Q6W5P4 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
MAPK1 P28482 1/20 0.34
LRRK2 Q5S007 1/20 0.33
PAX8 Q06710 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969835 0.95 PDE3B (0.38) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL3974525 0.85 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL7801329 0.84 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL3972062 0.81 LCK (0.50) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL3974523 0.81 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL3968748 0.79 LCK (0.49) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL3969076 0.76 LMNA (0.43) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL3969171 0.72 LCK (0.41) KDM4EHSD17B10LCKFYNNPSR1
SCHEMBL18309197 0.71 KDM4E (0.53) KDM4EALDH1A1HPGDHSD17B10LCK
SCHEMBL9985152 0.71 CYP3A4 (0.41) KDM4EALDH1A1LCKFYNELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 KDM4E 2767/4885ALDH1A1 198/4885HPGD 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.